Study shows lower risk of kidney cancer return

Medical experts completed the first successful clinical trial of an adjuvant treatment for kidney cancer patients they say reduces the likelihood of cancer returning.

Taking the oral tablet Sunitinib for one year, scientists report, reduced the chance of cancer returning for patients who had their kidney removed. The trial’s results were announced during the ESMO 2016 Congress in Copenhagen.
“This is a really positive result that could make a real difference to kidney cancer patients,” Royal Surrey County Hospital medical director Christopher Tibbs said in a press release. “The increase in ‘disease free time’ and the reduced risk of the disease returning will mean so much to these patients.”
Research on the oral tablet Sunitinib, presented during at the ESMO Congress, was comprised of a double-blind test involving 615 people with stage T3 renal cell carcinoma. Patients who received the tablet instead of the placebo were observed to experience improved disease-free survival. While the experimental group saw a measurable increase in side effects, scientists note the effects were manageable and did not negatively influence the quality of life for the patients.
“I’m delighted that we’ve seen such good results and will continue to support my clinical colleagues in their endeavors to always look for medical advancements and opportunities to achieve improved outcomes,” Tibbs added.
To read the full article CLICK here